NDA 013684 · Baxter Hlthcare
Osmitrol 20% In Water In Plastic Container
Mannitol · Injection · Osmotic Diuretic
Last checked: Nov 20, 2026Latest source record: Aug 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Jun 8, 1964
Approved uses
2
Original approval plus efficacy supplements
Registered trials
387
88 Phase 3, 30 recruiting
FAERS reports
4,991
4,752 serious, 1,439 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 26, 2025.
OSMITROL is indicated for: • The reduction of intracranial pressure and treatment of cerebral edema; • The reduction of elevated intraocular pressure. OSMITROL is an osmotic diuretic, indicated for the reduction of: • intracranial pressure and treatment of cerebral edema. ( 1 ) • elevated intraocular pressure. ( 1 )
Mechanism: Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate. This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 15, 2018 Supplement 104 · Efficacy LetterLabel
- Jun 8, 1964 Original approval · Type 5 - New Formulation or New Manufacturer
8 products under this application
- OSMITROL 20% IN WATER IN PLASTIC CONTAINER · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 5% IN WATER IN PLASTIC CONTAINER · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 20% IN WATER · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 5% IN WATER · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 15% IN WATER IN PLASTIC CONTAINER · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 10% IN WATER IN PLASTIC CONTAINER · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 15% IN WATER · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- OSMITROL 10% IN WATER · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Mannitol" as an intervention, any sponsor and status, largest first.
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingCompleted
Shanghai Institute Of Biological ProductsIndustry
NCT05158777 · 2,480 participants · Start Feb 13, 2022 · Primary completion Nov 14, 2022
Drug: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd · For: Varicella
Sites: Zhenzhou, China
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- Wheeze and Intermittent TreatmentPivotal-lookingCompleted
Queen Mary University of LondonAcademic, hospital or other
NCT01142505 · 1,358 participants · Start Nov 2010 · Primary completion Feb 2014
Drug: Mannitol; Montelukast · For: Wheezing
Sites: London, United Kingdom
- Acetaminophen-Mannitol Injection and Postoperative DeliriumPivotal-lookingRecruiting
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07235995 · 1,092 participants (planned) · Start Feb 2, 2026 · Primary completion Jan 31, 2027
Drug: Acetaminophen group; Sufentanil group · For: Postoperative Delirium
Sites: Changsha, China
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04401579 · 1,033 participants · Start May 8, 2020 · Primary completion Jul 31, 2020
Drug: Remdesivir; Baricitinib · For: COVID-19
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 71 sites in all
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04640168 · 1,010 participants · Start Dec 2, 2020 · Primary completion May 18, 2021
Drug: Baricitinib; Dexamethasone and 1 more · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 72 sites in all
- Transfusion-requirements in Septic Shock TrialPivotal-lookingCompleted
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT01485315 · 1,005 participants · Start Nov 2011 · Primary completion Mar 2014
Drug: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion · For: Septic Shock
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain623
- renal failure592
- anxiety505
- injury495
- drug ineffective488
- stress478
- unevaluable event470
- fear430
- death428
- off label use400
- renal impairment394
- emotional distress386
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 116 |
| 2005 | 80 |
| 2006 | 90 |
| 2007 | 59 |
| 2008 | 87 |
| 2009 | 73 |
| 2010 | 105 |
| 2011 | 578 |
| 2012 | 255 |
| 2013 | 106 |
| 2014 | 181 |
| 2015 | 126 |
| 2016 | 228 |
| 2017 | 259 |
| 2018 | 218 |
| 2019 | 190 |
| 2020 | 226 |
| 2021 | 307 |
| 2022 | 379 |
| 2023 | 394 |
| 2024 | 395 |
| 2025 | 318 |
| 2026 | 220 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
Tarrant BJ, Le Maitre C, Romero L, et al. · Respirology 2017 · Meta-Analysis, Systematic Review
- Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?
Lipworth BJ, Greig R, Chan R, et al. · Allergy 2025 · Comparative Study, Meta-Analysis
- Comparing the effects of mannitol and hypertonic saline in severe traumatic brain injury patients with elevated intracranial pressure: a systematic review and meta-analysis.
Karamian A, Seifi A, Lucke-Wold B · Neurol Res 2024 · Systematic Review, Meta-Analysis
- Hypertonic saline for traumatic brain injury: a systematic review and meta-analysis.
Gharizadeh N, Ghojazadeh M, Naseri A, et al. · Eur J Med Res 2022 · Meta-Analysis, Systematic Review
- Effectiveness of hypertonic saline infusion in management of traumatic brain injury: an updated systematic review and meta-analysis of randomized controlled trials.
Cai L, He W · Brain Inj 2024 · Systematic Review, Meta-Analysis
- Hypertonic Saline Versus Mannitol for Traumatic Brain Injury: A Systematic Review and Meta-analysis With Trial Sequential Analysis.
Schwimmbeck F, Voellger B, Chappell D, et al. · J Neurosurg Anesthesiol 2021 · Comparative Study, Meta-Analysis
Sponsor: Baxter Hlthcare · Also marketed as Osmitrol 5% In Water In Plastic Container, Osmitrol 20% In Water, Osmitrol 5% In Water, Osmitrol 15% In Water In Plastic Container, Osmitrol 10% In Water In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.